IVIG and COVID19
Phase 3
- Conditions
- COVID19.COVID19
- Registration Number
- IRCT20200501047259N1
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
stablished COVID 19 in PCR test
age more than 18
no response to at least one antiviral and chloroquine drugs
more than 30% involvement in chest computed tomography
Exclusion Criteria
pregnant women
coagulopathies
previous hypersensitivity to IVIG
left ventricular ejection fraction less than 35%
previous lung fibrosis or lung surgery
LUNG SARCOIDOSIS OR TUBERCULOSIS
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Increasing of patient's O2 saturation above 90%, improvement of lung involvement in lung CT scan. Timepoint: before discharge. Method of measurement: percentile.
- Secondary Outcome Measures
Name Time Method